News

As many as nine Pharma stocks, from Divi's Laboratories to Sun Pharma will be in focus on Monday, July 14, some due to their respective newsflow, while the rest due to brokerage commentary.As many as nine Pharma stocks will be in focus on Monday, July 14, some due to their respective newsflow, while the rest due to brokerage commentary. Here is a look at these names:Glenmark Pharma | Possibly the stock of Friday's session after a 10%-plus move, Glenmark will be in focus today as well after its Indore facility was issued a warning letter by the United States Food & Drug Administration (USFDA). The facility had received an Official Action Indicated (OAI) status in May after an inspection in February this year. The company believes this will not impact existing revenues, while it works to address the regulator's concerns. The stock is in the F&O ban today, which means that no new positions can be created in the stock.Divi's Laboratories | The Hyderabad-based drugmaker will in focus after MSN won the patent litigation related to Novartis's blockbuster cardiac drug Entresto. This clears the path for MSN to launch the generic version in the US market after July 15, 2025. Entresto API is expected to be the largest product in Divi’s innovator Custom Synthesis (CS) portfolio. Brokerage firm IIFL believes that Divi's could see a potential 12% to 13% decline in its annual Earnings before Interest, Tax, Depreciation and Amortisation (EBITDA) over the next year and this development poses a material risk to earnings.Wockhardt | The company has announced that it will be exiting the US Generics business as part of a broader realignment of the business. The US Generics business had reported a loss of $8 million in FY25. Wockhardt has filed for voluntary liquidation under Chapter 7 of the US Bankruptcy Code. The focus of the business now shifts to two new pillars, New Antibiotic Drug Discovery and Biologicals Portfolio in Insulin.Global Health | The Delhi High Court has refused to grant any potential stay or interim relief on the construction of a proposed 400-bed multispeciality hospital in Greater Kailash – 1. A writ petition had been filed before the Delhi High Court by the Greater Kailash Residents’ Association & Others. The hospital is being developed by GHL Hospital Limited, a Joint Venture between Global Health Ltd (Medanta) and DLF Ltd.Indegene | The company has launched NEXT Medical Writing Automation. The Platform combines generative AI (GenAI) with Indegene’s medical writing expertise. It tackles common challenges like tight timelines, fragmented data sources, complex and evolving regulatory landscape and also allows medical writing teams to scale output, reduce manual workload, and improve compliance accuracy.Sun Pharma | The next four stocks in the list are those on whom Morgan Stanley has initiated coverage. Sun Pharma is the only "Overweight" recommendation in this list. The brokerage has a target of ₹1,960 on the stock, which implies a potential upside of 17% from Friday's close.Lupin | Morgan Stanley has initiated coverage on Lupin with an "equalweight" rating and a price target of ₹2,096. It expects Lupin to have a strong first half of FY26 but US competition risk in key products later on will be a challenge.Dr. Reddy's Laboratories | FY26 will be a transition year for both Dr. Reddy's and Cipla as revenue from highly profitable gRevlimid tapers off. However, Semaglutide ramp-up could be an upside surprise. As a result, Morgan Stanley is "equalweight" on the stock with a price target of ₹1,298.Cipla | Lastly, Morgan Stanley has initiated coverage on Cipla with an "underweight" rating and a price target of ₹1,400, which implies a 6% downside for the stock. The brokerage is expecting Cipla's Earnings Per Share to have a negative 2% EPS Compounded Annual Growth Rate (CAGR) over financial year 2025-2027.NewsLive TVMarketPopular CategoriesCalculatorsTrending NowLet's Connect with CNBCTV 18Network 18 Group :©TV18 Broadcast Limited. All rights reserved.